Jun. 9 at 1:39 PM
Jupiter Neurosciences (NASDAQ:
$JUNS ), a B2i Digital Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.
Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.
Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/jupiter-neurosciences-1
The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:
• A
$100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech, putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at Nugevia.com
Register to attend:
https://goto.webcasts.com/starthere.jsp?ei=1757504&tp_key=cc5c9b4321&sti=juns
Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under
$JUNS.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://b2idigital.com/disclaimer.
